Endo International PLC (ENDP)
Россия
  • Россия
  • Украина

Endo International PLC (ENDP)

Contact Details

1400 Atwater Dr, Malvern, Pennsylvania, USA 19355-8701
(484) 216-0000
1400 Atwater Dr, Malvern, Pennsylvania, USA 19355-8701

General Information

Endo International plc is a global specialty healthcare company. It develops, manufactures, markets, and distributes quality branded pharmaceutical and generic products as well as medical devices. Endo offers branded prescription products, including Lidoderm, Opana ER, Percocet, Voltaren Gel, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel for pain, urology, endocrinology, and oncology. The company also provides non-branded generic products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women`s health, and hypertension markets. Endo International plc, formerly known as Endo Pharmaceuticals Holdings Inc., is headquartered in Dublin, Ireland.

Contact Information

Phone(484) 216-0000
Customer Service Phone(800) 947-5227
Fax(610) 558-8979
Website 1http://www.endo.com
FacebookFacebook
LinkedInLinkedIn
Twitter@endopharma_jobs
Thomson Reuters PermID5040791002

Executives

NamePositionTotal Annual CompensationYearPercent Change in Compensation
President and CEO$22,071,596201475.3%

Government Contracts

Corporate Data

Industries

  • Pharmaceutical Preparation Manufacturing

SIC Industries

  • Pharmaceutical Preparations

Company Size

Sales Volume$3.27 billion
Employees6,406

Ownership

Ticker SymbolENDP
ExchangeNASDAQ Global Select Market
State of IncorporationDelaware
Year Founded2014

Stocks

Previous Close28.30
Open28.48
Bid26.02 x 100
Ask26.03 x 39,700
Day`s Range25.67 - 28.50
52-Week Range26.91 - 95.92
Average Volume (1M)8,157,311
Forward P/E4.78x
Trailing P/E6.11x
Beta0.97x
Market Cap.$6,286.7 Million
Last Dividend Amount0
1y Target Price Est.92.89

Financials

Period EndingDec. 31, 2015Sep. 30, 2015Jun. 30, 2015Mar. 31, 2015
Total Revenue1,073,697745,727735,166714,128
Cost of Revenue810,067.9442,459438,858384,266
Gross Profit263,629.2303,268296,308329,862
Research Development43,98921,32718,98417,897
Selling General and Administrative212,014163,221154,491211,578
Depreciation and Amortization----
Other Operating Expenses211,139.1895,919121,34354,640
Total Operating Expenses1,277,2101,522,926733,676668,381
Other Income/Expenses Net(0.1)---
Earnings Before Interest and Taxes(203,512.9)(777,199)1,490.145,747
Interest Expense123,01896,44680,61173,139
Income Before Tax(353,228)(964,645)(103,614)(16,377)
Income Tax Expense(796,937)(160,939)(12,720)(166,869)
Minority Interest----
Net Income from Continuing Ops443,709(803,706)(90,894)150,492
Discontinued Operations(562,302)(246,782)(159,632)(226,210)
Extraordinary Items----
Effect of Accounting Changes----
Other Items13046107-
Net Income(118,463)(1,050,442)(250,419)(75,718)
Preferred Stock and Other Adjustments----
Net Income Applicable to Common Shares(118,463)(1,050,442)(250,419)(75,718)